Data at 2020 ASCO Virtual Scientific Program Demonstrates Strength of Nucleix’s Six-Marker Methylation-Based Assay Detecting Broad Array of Early Cancers

SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that it will present data from ongoing research using a blood-based methylation assay for cancer detection during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program held May 29-31, 2020. The six-marker assay serves as an initial component of Nucleix’s screening tests generating significant signal in early